Case Report: A Common Source Outbreak of Anisakidosis in the United States and Postexposure Prophylaxis of Family Collaterals

Aaron F. Carlin,^{1*} Shira Abeles,¹ Nathaniel A. Chin,² Grace Y. Lin,³ Maile Young,¹ and Joseph M. Vinetz^{1*}

¹Department of Medicine, School of Medicine, University of California, San Diego, California; ²Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin; ³Department of Pathology, UC San Diego Health, University of California, San Diego, California

Abstract. We present a case of intussusception with complete small bowel obstruction caused by intestinal anisakidosis requiring surgical resection. A 30-year-old man presented with acute onset of severe abdominal pain 3 days after eating home-cured salmon gravlax. Despite surgery, the patient developed recurrent abdominal pain on two occasions with evidence of continued inflammation proximal to the surgical anastomosis. He was then treated with albendazole and prednisone, and symptoms improved. A decision was made to prophylactically treat two asymptomatic family members who also consumed home-cured gravlax with albendazole, resulting in one individual passing an intact *Anisakis* worm in her stool. We suggest that albendazole therapy could be considered as a therapy for continued symptoms of anisakidosis and postexposure prophylaxis of *Anisakis* larvae ingestion from a common source.

INTRODUCTION

Anisakidosis is a human parasitic infection of the gastrointestinal tract. It is caused by the consumption of raw or inadequately cooked seafood containing nematode larvae of the family Anisakidae. On ingestion, *Anisakis* larvae can invade the gastrointestinal mucosa causing inflammation and thickening which can be complicated by small bowel obstruction, granuloma, and perforation.^{1,2} Symptoms may occur within hours or up to 2 weeks after ingestion of raw or undercooked seafood and can persist for months. During gastric anisakidosis, invasion of the gastric mucosa causes severe epigastric pain and vomiting, whereas intestinal invasion can cause acute onset abdominal pain with or without nausea, vomiting, and diarrhea. In chronic infections, individuals can complain of intermittent feelings of ill health and abdominal pain, lasting from several weeks to months.³ In gastric anisakidosis, endoscopy is both diagnostic, with larvae visually attached to the gastric mucosa with surrounding inflammation, and curative if the worm is removed. The diagnosis and treatment of enteric anisakidosis are more difficult. Surgery may be required for intestinal or extraintestinal infections that cause obstruction, appendicitis, or peritonitis. Albendazole is active against *Anisakis simplex* in vitro and in vivo against larvae in a guinea pig model.⁴ In addition, albendazole (400–800 mg daily for 6–21 days) treatment has been associated with therapeutic benefit in symptomatic individuals with presumptive enteric anisakidosis.^{5–8} However, the use of albendazole for post-exposure prophylaxis of asymptomatic individuals has not been reported.

CASE REPORT

A 30-year-old previously healthy man presented to the emergency department complaining of 2 days of intermittent progressive midepigastric abdominal pain. The pain was described as severe, sharp, non-radiating, and

associated with nausea and vomiting but without diarrhea. The patient first noted moderate intensity abdominal pain starting hours after ingesting home-cured salmon gravlax at a family dinner. This pain resolved spontaneously overnight but recurred the following day after he consumed more gravlax. His pain continued to worsen overnight, and the patient presented to the emergency room the following day. On presentation, he was afebrile and hemodynamically stable. His abdomen was diffusely tender in both upper quadrants but without rebound tenderness or guarding.

INVESTIGATIONS

Laboratory studies were notable for a white blood count of 12,000/mm³ (normal range 4,000–10,000/mm³), with 89% neutrophils (normal range 34–71%) and 1% eosinophils. computed tomography (CT) imaging of the abdomen showed proximal collapse of small bowel with distal dilation and high-grade obstruction with transition point. The patient was taken to the operating room for an emergent exploratory laparotomy. An intussusception with granulomatous lead point was identified in the mid-ileum, and a small bowel resection with primary anastomosis was performed.

DIAGNOSIS

Surgical pathology noted benign appearing small intestine with edematous lamina propria and abundant eosinophils extending to the serosal surface. In addition, foreign structures morphologically consistent with sections of *Anisakis* larvae were identified (Figure 1).

TREATMENT

The patient's abdominal pain and leukocytosis resolved following surgery but recurred abruptly 12 days post-operatively. He was readmitted with severe epigastric abdominal pain but was afebrile and hemodynamically stable similar to his initial presentation. His pain did not localize to his healing surgical site, which appeared clean, intact, and non-inflamed. His white blood count was 12,900 (normal range 4,000–10,000/mm³), with 81% neutrophils (normal range

* Address correspondence to Aaron F. Carlin, University of California San Diego, 9500 Gilman Dr., GPL Room 118, La Jolla, San Diego, CA 92093-0640, E-mail: acarlin@ucsd.edu or Joseph M. Vinetz, University of California San Diego, 9500 Gilman Dr., BRF2, La Jolla, San Diego, CA 92093-0760, E-mail: jvinetz@ucsd.edu.

FIGURE 1. Histopathologic findings from the small bowel showed areas of (A) severe inflammation with abundant eosinophils and lymphocytes (H&E $\times 40$). (B and C) Eosinophilic and lymphocytic inflammation surrounding larvae morphologically consistent with anisakidosis (H&E $\times 40$ and $\times 200$). This figure appears in color at www.ajtmh.org.

34–71%). Out of concern for retained embedded larvae in the small intestine, the patient was treated with albendazole 400 mg by mouth twice a day.^{7,8} He improved clinically, the leukocytosis resolved, and he was discharged with a plan to complete 6 days of albendazole as an outpatient. The day after completing his therapy, he developed acute onset severe periumbilical abdominal pain without nausea or vomiting. On presentation to the emergency department, he was afebrile and vital signs were normal. A CT abdomen showed segmental inflammation/enteritis proximal to the anastomosis. Thus, he was restarted on albendazole 400 mg BID for an additional 10 days, with the addition of prednisone 20 mg daily for 5 days. The patient completed albendazole and prednisone therapy without complications and has remained symptom free.

In addition to the patient, two other family members consumed the home-cured salmon gravlax that was the suspected source of *Anisakis* larvae. Although asymptomatic, they both described feeling the sensation of wriggling in their esophagus as they consumed the gravlax. They were very concerned about developing intestinal disease, given the severity of the patient's disease and need for surgical intervention. The family members were given 3-day courses of albendazole (400 mg BID). Both individuals completed treatment without side effects. After initiation of albendazole, one individual passed a 1.5-cm intact round worm consistent with *Anisakis* sp. in the stool (Figure 2). Both individuals remained asymptomatic after completing the therapy.

DISCUSSION

Intestinal anisakidosis is acquired following the ingestion of raw or inadequately prepared fish or squid. It is very likely that our patient and his family member were infected with *Anisakis* larvae after eating home-cured salmon gravlax. Using fresh wild sockeye salmon (*Oncorhynchus nerka*) purchased from a warehouse club, our patient marinated the fish in a salt and sugar brine solution for 48 hours before consumption. Pacific salmon have been implicated in the transmission of *Anisakis* sp. to humans. One study of 50 wild sockeye salmon caught during their spawning migration revealed that 100% were infected with larval *A. simplex*.^{9–11} Although salting fish can kill anisakid larvae, this requires high salt concentrations for prolonged periods of at least 5–6 weeks for all larvae to be killed.¹² Larvae can also be killed by heating to temperatures of $> 60^{\circ}\text{C}$ ($> 140^{\circ}\text{F}$) for at least 1 minute. To kill parasites in

seafood, the U.S. Food and Drug Administration recommends cooking to an internal temperature of at least 145°F , freezing at -20°C for at least 7 days, or flash freezing at -35°C until solid for at least 15 hours.¹³

Our patient developed postsurgical recurrence of abdominal pain and leukocytosis. This raised the concern that embedded larvae still remained in sections of the small intestine.

FIGURE 2. Image of a white, slender, 1.5-cm worm morphological consistent with *Anisakis* spp., passed in the stool of one family member after treatment with albendazole. This figure appears in color at www.ajtmh.org.

Although surgical removal of the larvae can be definitive treatment of anisakidosis, pharmacologic therapy with albendazole or steroids may lead to clinical resolution in cases of intestinal anisakidosis without surgical intervention.^{5–8,14} Albendazole is a broad-spectrum anthelmintic agent that inhibits tubulin polymerization and the microtubule-dependent uptake of glucose.¹⁵ Based on its clinical efficacy in the treatment of many intestinal and tissue nematodes, and its activity against *Anisakis* larvae in preclinical models, albendazole could be an effective therapy for anisakidosis.^{4,16} To date, a small number of reports suggest that albendazole provides therapeutic benefit in symptomatic individuals with presumptive enteric anisakidosis.^{5–8} Besides albendazole, Ramos et al.¹⁴ reported a series of five patients presenting with acute intestinal anisakidosis with segmental intestinal obstruction on CT in Spain who were treated nonoperatively with 6-methylprednisolone (1 mg/kg/24 hours) for 5 days. All of these patients had clinical and radiographic disease resolution without adverse reactions. It is thought that burrowing or dead *Anisakis* larvae causes an intense Th2 immune response with eosinophils and lymphocytes infiltrating the mucosa and submucosa.⁵ Corticosteroids could theoretically be beneficial in cases of intestinal anisakidosis because of their anti-inflammatory effects and because they may aid in the resolution of bowel obstruction.¹⁷ In our patient, a short course of albendazole was prescribed for postoperative recurrence of abdominal pain. After an initial response, the patient relapsed after albendazole completion and represented with evidence of intestinal inflammation on CT imaging. Because of his persistent symptoms and radiographic findings, we opted to extend the duration of albendazole treatment and add oral prednisone at 20 mg daily for 5 days. The patient's symptoms resolved completely without adverse events on this therapy.

To our knowledge, no previous report has discussed prophylactic therapy in asymptomatic individuals following common source exposure to *Anisakis* larvae. Given the high likelihood of exposure and the beneficial safety profile of albendazole, we ultimately decided to prescribe a 3-day course of albendazole at 400 mg BID to two family members who also consumed the salmon gravlax. Although we cannot know if the treatment prevented the development of clinical disease, it is likely that it had the intended antiparasitic effect as evidenced by the passage of an intact worm. Based on this case, we suggest that albendazole therapy could be considered postexposure prophylaxis for known or suspected common source exposure to *Anisakis* spp. larvae.

Received July 16, 2018. Accepted for publication July 29, 2018.

Published online September 17, 2018.

Conflicts of interest: M. Y. reports personal fees (advisory board) and others from Gilead Sciences outside the submitted work.

Authors' addresses: Aaron F. Carlin, Shira Abeles, Maile Young, and Joseph M. Vinetz, Department of Medicine, School of Medicine, University of California, San Diego, CA, E-mails: acarlin@ucsd.edu, sabeles@ucsd.edu, m1young@ucsd.edu, and jvinetz@ucsd.edu. Nathaniel A. Chin, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, E-mail: nachin@wisc.edu. Grace Y. Lin, Department of Pathology, UC San Diego Health, University of California, San Diego, CA, E-mail: g4lin@mail.ucsd.edu.

REFERENCES

1. Ishikura H, Kikuchi K, Nagasawa K, Ooiwa T, Takamiya H, Sato N, Sugane K, 1993. Anisakidae and anisakidosis. *Prog Clin Parasitol* 3: 43–102.
2. Lopez Penas D, Ramirez Ortiz LM, del Rosal Palomeque R, Lopez Rubio F, Fernandez-Crehuet Navajas R, Mino Fugarolas G, 2000. Study of 13 cases of anisakiasis in the province of Cordoba. *Med Clin (Barc)* 114: 177–180.
3. Bouree P, Paugam A, Petithory JC, 1995. Anisakidosis: report of 25 cases and review of the literature. *Comp Immunol Microbiol Infect Dis* 18: 75–84.
4. Dziekonska-Rynko J, Rokicki J, Jablonowski Z, 2002. Effects of ivermectin and albendazole against *Anisakis simplex* in vitro and in guinea pigs. *J Parasitol* 88: 395–398.
5. Hochberg NS, Hamer DH, 2010. Anisakidosis: perils of the deep. *Clin Infect Dis* 51: 806–812.
6. Ioli A, Leonaldi R, Gangemi C, Lo Giudice L, Bottari M, Petithory JC, 1998. Apropos of 1 case of anisakiasis contracted in Sicily. *Bull Soc Pathol Exot* 91: 232–234.
7. Moore DA, Girdwood RW, Chiodini PL, 2002. Treatment of anisakiasis with albendazole. *Lancet* 360: 54.
8. Pacios E, Arias-Diaz J, Zuloaga J, Gonzalez-Armengol J, Villarreal P, Balibrea JL, 2005. Albendazole for the treatment of anisakiasis ileus. *Clin Infect Dis* 41: 1825–1826.
9. Deardorff TL, Kayes SG, Fukumura T, 1991. Human anisakiasis transmitted by marine food products. *Hawaii Med J* 50: 9–16.
10. Deardorff TL, Kent ML, 1989. Prevalence of larval *Anisakis simplex* in pen-reared and wild-caught salmon (*Salmonidae*) from Puget Sound, Washington. *J Wildl Dis* 25: 416–419.
11. Kliks MM, 1983. Anisakiasis in the western United States: four new case reports from California. *Am J Trop Med Hyg* 32: 526–532.
12. Horst Karl AR, Huss HH, Bloemsma B, 1995. Survival of *Anisakis* larvae in marinated herring fillets. *Int J Food Sci Technol* 29: 661–670.
13. Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food Safety, 2011. *Fish and Fishery Products Hazards and Controls Guidance*, 4th edition. College Park, MD: Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food Safety.
14. Ramos L, Alonso C, Guilarte M, Vilaseca J, Santos J, Malagelada JR, 2005. *Anisakis simplex*-induced small bowel obstruction after fish ingestion: preliminary evidence for response to parenteral corticosteroids. *Clin Gastroenterol Hepatol* 3: 667–671.
15. Lacey E, 1990. Mode of action of benzimidazoles. *Parasitol Today* 6: 112–115.
16. Rossignol JF, Maisonneuve H, 1983. Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis. *Trans R Soc Trop Med Hyg* 77: 707–711.
17. Feuer DJ, Bradley KE, 2000. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. *Cochrane Database Syst Rev* 2: CD001219.